Soluble type III TGFβ receptor in diagnosis and follow-up of patients with breast cancer

被引：12

作者：

Jurisic, Darko ^{[1
]}

Erjavec, Igor ^{[2
]}

Trkulja, Vladimir ^{[3
]}

Dumic-Cule, Ivo ^{[2
]}

Hadzibegovic, Irzal ^{[4
]}

Kovacevic, Lucija ^{[2
]}

Svagusa, Tomo ^{[2
]}

Stanec, Zdenko ^{[5
]}

Vukicevic, Slobodan ^{[2
]}

Grgurevic, Lovorka ^{[2
]}

机构：

[1] Gen Hosp, Dept Surg, Slavonski Brod, Croatia

[2] Univ Zagreb, Sch Med, Ctr Translat & Clin Res, Lab Mineralized Tissues, Salata 11, HR-10000 Zagreb, Croatia

[3] Univ Zagreb, Sch Med, Dept Pharmacol, HR-10000 Zagreb, Croatia

[4] Gen Hosp, Dept Cardiol, Slavonski Brod, Croatia

[5] Univ Hosp Dubrava, Dept Plast Reconstruct & Aesthet Surg, Zagreb, Croatia

来源：

GROWTH FACTORS | 2015年 / 33卷 / 03期

关键词：

TGF; TGFrIII; betaglycan; breast cancer; biomarker; GROWTH-FACTOR-BETA; SUPPRESSES TUMORIGENICITY; MEMBRANE PROTEOGLYCAN; BETAGLYCAN; EXPRESSION; BONE; METASTASIS; INHIBITION; PATHWAY; POTENT;

D O I：

10.3109/08977194.2015.1055740

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Type III transforming growth factor (TGF) receptor (TGFrIII) modulates TGF superfamily signaling. Its tumor tissue expression is downregulated in human breast cancer. We determined (indirect ELISA) plasma levels of the soluble receptor (sTGFrIII) in 47 women with breast cancer (AJCC stages 0-IIB) (cases) pre-surgery and over two months after the surgery, and in 36 healthy women (controls). Plasma sTBFrIII was lower in cases than in the controls (age-adjusted difference -29.7ng/mL, p<0.001), and discriminated between disease and health (sensitivity and specificity 100% at 16.6ng/mL). With adjustment for age, AJCC stage, lymph node involvement, HER2 and hormone receptor status, higher pre-surgery sTBFrIII was associated with better progression-free survival (HR=0.68, 95%CI 0.49-0.89, p=0.004). An increasing trend in plasma sTBFrIII was observed over 2 months after the surgery (0.6% increase/day, p<0.001), consistently across the patient subsets. Data suggest a high potential of plasma sTBFrIII as a novel diagnostic and prognostic biomarker in breast cancer.

引用

页码：200 / 209

页数：10

共 50 条

[31] The type III TGF-β receptor suppresses breast cancer progression
Dong, Mei
How, Tam
Kirkbride, Kellye C.
Gordon, Kelly J.
Lee, Jason D.
Hempel, Nadine
Kelly, Patrick
Moeller, Benjamin J.
Marks, Jeffrey R.
Blobe, Gerard C.
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01): : 206 - 217
[32] Determinants of the Type of Oncologists Providing Breast Cancer Follow-up
Neuman, H. B.
Schumacher, J. R.
Schneider, D. F.
Winslow, E. R.
Schmocker, R.
Busch, R. A.
Tucholka, J.
Smith, M. A.
Greenberg, C. C.
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S135 - S135
[33] Scintimammography:: a new imaging technique for diagnosis and follow-up of breast cancer
Hermans, J
Bodart, F
François, D
Merlo, P
Fauconnier, JP
Schmitz, A
Gérard, R
de Ruyver, D
Eeckhoudt, L
BULLETIN DU CANCER, 2000, 87 (04) : 334 - 340
[34] DIAGNOSIS AND TREATMENT OF BREAST-CANCER RECURRENCES IN TUMOR FOLLOW-UP
DELBRUCK, H
MEDIZINISCHE WELT, 1986, 37 (19): : 614 - 617
[35] Breast cancer follow-up after a primary diagnosis: A confused picture
Cruickshank, Susanne
Barber, Matthew
BREAST, 2019, 46 : 97 - 100
[36] Use of serum tumor markers for the diagnosis and follow-up of breast cancer
Barrenetxea, G
Schneider, J
Llorente, MF
ONCOLOGY, 1998, 55 (05) : 447 - 449
[37] Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients
Huang, Zhao Hui
Li, Li Hua
Hua, Dong
CANCER LETTERS, 2006, 243 (01) : 64 - 70
[38] Follow-up for patients with breast cancer - who benefits? The patients' view
不详
EJC SUPPLEMENTS, 2006, 4 (02): : 53 - 53
[39] Follow-Up of Breast Cancer Survivors
Warner, Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) : 1893 - 1893
[40] FOLLOW-UP IN BREAST-CANCER
DEWAR, J
BMJ-BRITISH MEDICAL JOURNAL, 1995, 310 (6981): : 685 - 686

← 1 2 3 4 5 →